Skip to content

Canadian Medical Association Journal

ISSN 0820-3946

5 papers in the library · 244 citations · publishing 2015-2022

Papers

Psychedelic medicine: a re-emerging therapeutic paradigm

Canadian Medical Association Journal September 8, 2015 Kenneth W. Tupper, Evan Wood, Richard Yensen et al. 189 citations

Clinical research worldwide is again investigating psychedelic substances as treatments for addiction, depression, anxiety, and PTSD. This renewed interest follows a period of research that ran from the 1950s until it was terminated, and the abstract indicates that current studies are exploring these substances' therapeutic potential for those conditions.

Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache

Canadian Medical Association Journal February 16, 2016 Wm. Jeptha Davenport 14 citations

Cluster headaches, which affect about 0.1% of the population, are a focus for extending research on psychedelic drugs as adjuncts to psychotherapy, according to Tupper and colleagues. The renewed clinical interest in these substances includes their potential application in headache medicine, particularly for treating cluster headache episodes.

High time? Psychedelics on cannabis-like fast track to legalization

Canadian Medical Association Journal December 18, 2022 Kevin Zannese 9 citations

Alberta is set to become the first province to regulate psychedelic-assisted therapy. As with cannabis, the push for medical access to psychedelics is moving faster than the research needed to guide their use. Health Canada recently changed its Special Access Program to let physicians request such therapies.

Policy in focus: Is psilocybin the next cannabis?

Canadian Medical Association Journal November 14, 2021 Greg Basky 7 citations

Interest in using psilocybin (the active compound in 'magic mushrooms') for therapy is increasing, while unregulated dispensaries selling psychedelics proliferate in Canada and the United States. Over the past ten years, research into the clinical application of psychedelics for conditions such as depression and addiction has undergone a revival.